{"id":"W3135437596","doi":"10.1016/j.annonc.2021.01.020","title":"7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sierra Oncology; Eisai; Incyte; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Servier; Amgen","keywords":"Medicine; Tolerability; Discontinuation; Internal medicine; Adverse effect; Clinical endpoint; Pharmacodynamics; Refractory (planetary science); Lymphoma; Pharmacokinetics; Neutropenia; Gastroenterology; Oncology; Toxicity; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001839683,0.000714997,0.0013489,0.0005432472,0.0003416766,0.001220425,0.000710076,0.0008112454,0.006069086],"category_scores_gemma":[0.002643133,0.000274394,0.001502213,0.0008564721,0.0002245309,0.0006777208,0.0004031553,0.001573035,0.001274952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074311,"about_ca_system_score_gemma":0.001492239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004081325,"about_ca_topic_score_gemma":0.01388248,"domain_scores_codex":[0.9993886,0.0002208701,0.00005992011,0.00007898548,0.0001488215,0.0001028427],"domain_scores_gemma":[0.9983099,0.0005144507,0.000375474,0.0001314137,0.000328297,0.0003404521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.18174,0.005258756,0.06699727,0.004396406,0.006950786,0.0005373249,0.0002189684,0.004278051,0.02909192,0.0008181186,0.1330234,0.5666892],"study_design_scores_gemma":[0.1711209,0.08313829,0.3386736,0.001070671,0.01833325,0.002820134,0.0002503185,0.002434959,0.01180854,0.00157841,0.3685656,0.0002054466],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6940641,0.07404164,0.004450294,0.01087726,0.003113326,0.004624859,0.1513744,0.0009288067,0.0565253],"genre_scores_gemma":[0.7307047,0.03029098,0.009875002,0.01533269,0.001189492,0.003283862,0.1909933,0.0003453841,0.01798448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006069086,"threshold_uncertainty_score":0.02030313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05688993279910743,"score_gpt":0.3954258355846018,"score_spread":0.3385359027854943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}